Salicin inhibits AGE-induced degradation of type II collagen and aggrecan in human SW1353 chondrocytes: therapeutic potential in osteoarthritis
Source abstract
Abstract
Osteoarthritis (OA) is a major age-related disease, which may be caused by the accumulation of advanced glycation end-products (AGEs). Excessive degradation of type II collagen and aggrecan by matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinase with thrombospondin type 1 motif (ADAMTS) induced by AGEs is a pivotal event in the pathogenesis of osteoarthritis. In addition, activation of the nuclear factor-κB (NF-κB) pathway induces the expression of a cascade of proinflammatory cytokines, such as interleukin (IL)-1β and tumor necrosis factor-α (TNF-α). In the present study, we investigated the effects of salicin, one of the main constituents of aspirin and a derivative of Alangium chinense, on AGE-induced degradation of the articular extracellular matrix in SW1353 human chondrocytes. Our findings reveal a novel beneficial role of salicin in rescuing degradation of type II collagen and aggrecan, reducing oxidative stress, attenuating expression of proinflammatory cytokines, and inhibiting activation of the NF-κB proinflammatory signaling pathway in chondrocytes stimulated with AGEs. Salicin may thus have potential as a safe and effective therapy against the development and progression of OA.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Inflammatory mediators and NSAID effects · Advanced Glycation End Products research · Osteoarthritis Treatment and Mechanisms
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Orthopedics, The Second Hospital of Jilin University
Department of Spine Surgery, The Second Hospital of Jilin University
References (32)
Show source-provided references
1. 10.1021/np400074710.1021/np4000747 ↗
2. 10.1007/978-981-10-8022-7_5910.1007/978-981-10-8022-7_59 ↗
3. Lin C, Cai J, Xu Y, et al. Effect of Alangium chinense on CYP450 isoforms activity of rats. Int J Clin Exp Med. 2016;9:3097–3103.
4. Aboelsoud N. Herbal medicine in ancient Egypt. J Med Plants Res. 2010;4:82–86.
5. Duan H, Zhai KF, Gao GZ, et al. Macroporous resin adsorption for purification of salicin from Alangium chinense (Lour.) Harms. Food Sci. 2012;33:99–102.
6. 10.3390/molecules1907968910.3390/molecules19079689 ↗
7. 10.1080/10286020.2015.108255110.1080/10286020.2015.1082551 ↗
8. Zabihi NA, Mahmoudabady M, Soukhtanloo M, et al. Salix alba attenuated oxidative stress in the heart and kidney of hypercholesterolemic rabbits. Avicenna J Phytomed. 2018;8:63.
9. 10.1007/s00228010032510.1007/s002280100325 ↗
10. 10.3389/fimmu.2016.0020610.3389/fimmu.2016.00206 ↗
11. 10.1002/1529-0131(200201)46:1<114::AID-ART10025>3.0.CO;2-P10.1002/1529-0131(200201)46:1<114::AID-ART10025>3.0.CO;2-P ↗
12. 10.3892/mmr.2016.552310.3892/mmr.2016.5523 ↗
13. P. Garnero. Chapter 8 – biochemical markers of osteoarthritis. In Sharma L, Berenbaum F. Osteoarthritis. Mosby; 2007. p. 113–130.
14. 10.1016/j.febslet.2007.03.09010.1016/j.febslet.2007.03.090 ↗
15. 10.1002/jcb.2329810.1002/jcb.23298 ↗
16. 10.1016/S1471-4914(03)00031-510.1016/S1471-4914(03)00031-5 ↗
17. 10.1016/j.joca.2018.02.18110.1016/j.joca.2018.02.181 ↗
18. 10.1186/s40659-015-0057-010.1186/s40659-015-0057-0 ↗
19. 10.1089/dna.2013.219810.1089/dna.2013.2198 ↗
20. 10.2119/molmed.2011.0038910.2119/molmed.2011.00389 ↗
21. 10.1038/nrrheum.2011.22210.1038/nrrheum.2011.222 ↗
22. 10.1016/j.bbadis.2016.01.00310.1016/j.bbadis.2016.01.003 ↗
23. 10.3390/antiox603005110.3390/antiox6030051 ↗
24. 10.1111/j.1582-4934.2006.tb00407.x10.1111/j.1582-4934.2006.tb00407.x ↗
25. 10.1038/nrrheum.2010.19610.1038/nrrheum.2010.196 ↗
26. 10.1074/jbc.M111.26454910.1074/jbc.M111.264549 ↗
27. 10.1016/j.joca.2006.04.00810.1016/j.joca.2006.04.008 ↗
28. 10.1016/j.cca.2006.07.01910.1016/j.cca.2006.07.019 ↗
29. 10.1186/ar244010.1186/ar2440 ↗
30. 10.1097/BOR.0b013e328349c2b110.1097/BOR.0b013e328349c2b1 ↗
31. 10.1016/S1471-4892(02)00165-010.1016/S1471-4892(02)00165-0 ↗
32. 10.1016/j.biocel.2013.08.01810.1016/j.biocel.2013.08.018 ↗